Cellestia is a biopharmaceutical company developing innovative first-in-class anti-cancer drugs. Our clinical stage lead compound CB-103 is a selective oncogene transcription factor inhibitor for treatment of currently untreatable cancers driven by oncogenic activation of NOTCH.
Cooperation possibilities
R&D, co-development, licensing
- http://www.cellestia.com
- +41 61 633 29 80
